Armata (NASDAQ: ARMP) director receives 25,640 stock options at $11.61 strike

Rhea-AI Filing Summary

Armata Pharmaceuticals director Odysseas D. Kostas received a new stock option grant as equity compensation. On March 9, 2026, he was granted options covering 25,640 shares of Common Stock at an exercise price of $11.61 per share. The options have no cash cost at grant and expire on March 9, 2036. According to the disclosure, the entire grant will vest on March 9, 2027, provided he remains in continuous service through that date, and he now holds 25,640 options following this award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Odysseas Kostas D

(Last) (First) (Middle)

5005 MCCONNELL AVENUE

(Street)

LOS ANGELES CA 90066

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Armata Pharmaceuticals, Inc. [ ARMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$11.61	03/09/2026		A		25,640		(1)	03/09/2036	Common Stock	25,640	$0.00	25,640	D

Explanation of Responses:

1. The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.

	/s/ Odysseas Kostas	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Armata Pharmaceuticals (ARMP) director Odysseas Kostas report on this Form 4?

Director Odysseas D. Kostas reported receiving a grant of 25,640 stock options. These options relate to Armata Pharmaceuticals Common Stock and represent a compensation award rather than an open-market purchase or sale of existing shares.

What are the key terms of the new Armata Pharmaceuticals (ARMP) stock options?

The grant covers 25,640 options with an exercise price of $11.61 per share. The options are scheduled to expire on March 9, 2036, giving the director a long-dated right to buy Armata Pharmaceuticals Common Stock at that price.

When do the Armata Pharmaceuticals (ARMP) options granted to Odysseas Kostas vest?

The options are scheduled to vest in full on March 9, 2027. Vesting is conditioned on Dr. Kostas remaining in continuous service through that date, aligning the award with a one-year service requirement from the grant date.

Did the Armata Pharmaceuticals (ARMP) director buy or sell shares in the market?

No open-market buy or sell occurred; the filing shows a grant of stock options. This is a compensation-related acquisition coded as an award, not a purchase or sale of existing Common Stock in the public market.

How many Armata Pharmaceuticals (ARMP) options does Odysseas Kostas hold after this grant?

After this transaction, Dr. Kostas holds 25,640 stock options directly. This reflects the newly granted award reported, with the filing showing this as his total options position following the grant.

What does the zero price in the Armata Pharmaceuticals (ARMP) Form 4 mean?

The transaction price per share is shown as $0.00 because this is a grant of options, not a purchase. The economic term that matters is the exercise price of $11.61, which is what must be paid to acquire shares in the future.